Bullish & Foolish
Full IBRX fundamentals All 466 on the Survival Watch

IBRXIMMUNITYBIO, INC.

Is Immunitybio struggling financially?

Yes, by its own account. Immunitybio told the SEC on 7 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$8.3B
Source filing
10-Q 7 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 2months

    If it eases off

    Empty by Aug 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$75.7M

÷

Cash burned over the last 12 months

$533.1M

What Immunitybio told the SEC

As a result of continuing anticipated operating cash outflows as we commercialize our approved product and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product;…

IMMUNITYBIO, INC., Form 10-Q, filed 7 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 19.3% share-count increase The company issued stock. Each share now owns 16.2% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt